This is a working overview of albumin binding, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-11-20. Anything still debated is marked as such rather than presented as settled.
Pharmacological activity arises from agonism at the glucagon-like peptide-1 receptor, a G protein-coupled receptor expressed in the pancreas, the gastrointestinal tract, and the brainstem. Receptor activation raises intracellular cyclic adenosine monophosphate and enhances insulin release in a glucose-dependent manner, an effect that diminishes when blood glucose concentration is low. Other effects include slowed gastric emptying and hypothalamic satiety signalling. These pathways are described well. Receptor desensitisation rates across tissues, relative to the endogenous hormone, are still under investigation, and reported findings differ between laboratories.
The company that developed the compound filed it as a long-acting analogue, and it gained first approval in 2017 for type 2 diabetes. Later authorisations from several regulators extended the indication to chronic weight management, and the World Health Organization added the glucagon-like peptide-1 receptor agonist drug class to its model list of essential medicines in 2023. Production uses solid-phase peptide synthesis followed by side-chain conjugation and chromatographic purification. Supply constraints and cost differences across regions are well documented. Literature on long-term outcomes continues to grow, with many trials reporting surrogate endpoints rather than hard clinical endpoints.
Semaglutide is a synthetic peptide analog of human glucagon-like peptide-1, developed by Novo Nordisk and first approved in 2017 for type 2 diabetes. It belongs to the incretin mimetic class, a group of agents that reproduce the glucose-dependent actions of endogenous GLP-1. The molecule was engineered to resist degradation by dipeptidyl peptidase-4 and to bind serum albumin, extending its half-life from minutes to roughly one week. Approval for chronic weight management followed in 2021, based on large cardiovascular and obesity outcome trials.
GLP-1 receptors are expressed on pancreatic beta cells, in the gut, and in several brain regions. Receptor activation raises cyclic AMP, enhances glucose-dependent insulin secretion, and suppresses glucagon release when blood glucose is high. Effects on gastric emptying and on hypothalamic appetite circuits reduce energy intake. Because insulin release remains glucose-dependent, the risk of hypoglycemia is low when the drug is used alone. The precise contribution of each pathway to body weight change in humans remains an area of active investigation.
Clinical studies of semaglutide generally measure glycated hemoglobin, fasting plasma glucose, body weight, and composite cardiovascular endpoints. The SUSTAIN program enrolled adults with type 2 diabetes, while the STEP program focused on obesity without diabetes. Administration follows a stepwise escalation schedule designed to limit gastrointestinal effects during the first weeks. Reported outcomes include mean percentage weight change, the proportion of participants reaching defined weight-loss thresholds, and rates of nausea, vomiting, and diarrhea. Long-term data on durability after treatment stops are still limited and remain a topic of ongoing research.
| Property | Value | Notes |
|---|---|---|
| Molecular class | 31-amino-acid peptide | Modified glucagon-like peptide-1 analogue |
| Molecular mass | approximately 4114 Da | Calculated for the free peptide backbone |
| Appearance | white to off-white powder | Typical of purified lyophilised peptide batches |
| Solubility class | freely soluble in water | Aqueous solubility improves at slightly alkaline pH |
| Typical storage | -20 degrees Celsius, dry, dark | Protect from repeated freeze-thaw cycles |
Fodor's Flashmaps New York, 1991 Fodor's See It New York City, 2004, ISBN 1-4000-1387-9 Valentine's Manual of Old New York / No. 7, Ed. Henry Collins Brown, Pub. Valentine's Manual Inc. 1922 Further reading
Hepatalin is a hormone produced by the liver after feeding and plays a central role in the partitioning of the storage of nutrient energy by its action on glucose uptake and formation of glycogen in muscle. Hepatalin accounts for the majority of postprandial glucose uptake. Hepatalin secretion from the liver is regulated by three signals: a hepatic parasympathetic-mediated signal, elevated hepatic glutathione (GSH), and pulses of insulin.
=== Recombinant human CNTF (Axokine) === A recombinant version of human CNTF (rhCNTF), trade name Axokine, is a modified version with a 15 amino acid truncation of the C-terminus and two amino acid substitutions. It is three to five times more potent than CNTF in in vitro and in vivo assays and has improved stability properties. Like CNTF it is a neurotrophic factor, and may stimulate nerve cells to survive. It was tested in the 1990s as a treatment for amyotrophic lateral sclerosis. It did not improve muscle control as much as expected, but trial participants did report a loss of appetite. Phase III clinical trials for the drug against obesity were conducted in 2003 by Axokine's maker, Regeneron Pharmaceuticals, demonstrating a small positive effect in some patients, but the drug was not commercialized. A major problem with the treatment was that in nearly 70% of the subjects tested, antibodies against Axokine were produced after approximately three months of treatment. In the minority of subjects who did not develop the antibodies, weight loss averaged 12.5 pounds in one year, versus 4.5 pounds for placebo-treated subjects. In order to obtain this benefit, subjects needed to receive daily subcutaneous injections of one microgram Axokine per kilogram body weight. Xencor patent application raises the disturbing idea that subjects producing antibodies against CNTF analogues may eventually suffer severe adverse effects, as these antibodies could potentially interfere with the neuroprotective functions of endogenous CNTF.
Sources: en.wikipedia.org
As mentioned above, in field-flow fractionation the field can be hydraulic (with a cross flow through a semi-permeable membrane as the accumulation wall), gravitational, centrifugal, thermal, electrical, or magnetic. In all cases, the separation mechanism is produced by differences in particle mobility under the forces of the field, in a stationary equilibrium with the forces of diffusion: The field induces a downward drift velocity and concentration towards the accumulation wall, the diffusion works against this concentration gradient. After a certain time (called relaxation time) the two forces equilibrate in a stationary equilibrium. This is best visualized as a particle cloud, with all components in constant motion, but with an exponential decrease of the average concentration going away from the accumulation wall up into the channel. The decrease of air pressure going up from sea level has the same exponential decrease which is described in the barometric formula. After relaxation has been achieved, elution starts as the channel flow is activated. In the thin channel (typical height 250 to 350 μm) a parabolic laminar-flow-velocity profile exists, which is characterized by a strong increase of the flow velocity with increasing distance from the accumulation wall. This determines the velocity of a particular particle, based on its equilibrium position from the wall of the channel. Particles closer to the accumulation wall will migrate slower compared to others being higher up.
Neurons, also called nerve cells, are the functional electrically excitable cells of the brain. They can only function in collaboration with other neurons and interneurons in a neural circuit. There are an estimated 100 billion neurons in the human brain. Neurons are polarised cells that are specialised for the conduction of action potentials also called nerve impulses. They can also synthesise membrane and protein. Neurons communicate with other neurons using neurotransmitters released from their synapses, and they may be inhibitory, excitatory or neuromodulatory. Neurons may be termed by their associated neurotransmitter such as excitatory dopaminergic neurons and inhibitory GABAergic neurons. Cortical interneurons only make up around a fifth of the neuronal population but they play a major role in modulating cortical activity needed for cognition and many aspects of learning and memory. Cortical interneurons vary in shape, molecular make-up, and electrophysiology; they function collectively to maintain the balance between excitation and inhibition in the cortex primarily through the use of GABA. Disruption of this balance is a common feature of neuropsychiatric disorders such as schizophrenia. A cause of the disruption can occur in prenatal development through the exposure to chemicals and environment. In the cerebral cortex different neurons occupy the different cortical layers and include the pyramidal neurons and rosehip neurons. In the cerebellum Purkinje cells and interneuronal Golgi cells predominate.
Ion mobility spectrometry (IMS) is a technique of ion separation in gaseous phases based on their differences in ion mobility when an electric field is applied providing spatial separation prior to MS analysis. With the introduction of DESI as an ion source for ion mobility mass spectrometry, applications for IMS have expanded from only vapor-phase samples with volatile analyses to also intact structures and aqueous samples. When coupled to a time-of-flight mass spectrometer, analysis of proteins is also possible. These techniques work in tandem to one another to investigate ion shapes and reactiveness after ionization. A key characteristic of this setup is its ability to separate the distribution of ions generated in DESI prior to mass spectrometry analysis.
(1908), chairman of Citigroup 1948–1952 Edmond Guggenheim (1908), mining executive, grandson of Meyer Guggenheim Ward Melville (1909), founder of the Melville Corporation that owned CVS Health, Marshalls, and Thom McAn shoes; helped the establishment of Stony Brook University and Stony Brook Village Center John Vernou Bouvier III* (1914), stockbroker and socialite, father of Jacqueline Kennedy Onassis, transferred to Yale College after two years Armand G. Erpf (1917), senior partner at Loeb, Rhoades & Co., chairman of the Crowell-Collier Publishing Company, financial architect of the New York magazine Alan H. Kempner (1917), stockbroker and publishing executive, son-in-law of banker Carl M. Loeb Lindsley F. Kimball (1917), former president of United Service Organizations and National Urban League Charles Bierer Wrightsman (1918), oil executive and art collector Armand Hammer (1919), philanthropist, chairman of Occidental Petroleum, namesake of Hammer Museum and Armand Hammer United World College of the American West George E. Jonas (1919), partner at Pellessier-Jonas-Rivet Manufacturing Co., philanthropist and founder of Camp Rising Sun S. Marshall Kempner (1919), investment banker, and brother-in-law of Peggy Guggenheim John S. Sinclair (1920), fourth president of the Federal Reserve Bank of Philadelphia, former president of The Conference Board Charles M.
Sources: en.wikipedia.org
== History == Acetalated dextran was first reported in 2008 out of the lab of Jean Fréchet at the University of California, Berkeley in the College of Chemistry by inventors Eric Bachelder, Tristan Beaudette and Kyle Broaders. This version of acetalated dextran, often abbreviated Ac-DEX, has dextran and exceedingly low levels of acetone and methanol as degradation products. In 2012, in the laboratory of Kristy Ainslie, at Ohio State University in the College of Pharmacy, polymer synthesis was modified to release ethanol in place of methanol upon degradation. The ethanol producing version of acetalated dextran is often abbreviated Ace-DEX.
==== I. Lipophilic Drugs ==== Microbubbles can facilitate the local targeting of hydrophobic drugs through the incorporation of these agents into the microbubble lipid shell. This encapsulation technique reduces systemic toxicity, increases drug localization, and improves the solubility of hydrophobic drugs. For increased localization, a targeting ligand can be appended to the exterior of the microbubble. This improves treatment efficacy. One drawback of the lipid-encapsulated microbubble as a drug delivery vehicle is its low payload efficacy. To combat this, an oil shell can be incorporated to the interior of the lipid monolayer to enhance payload efficacy.
Wood pulp made from birch gives relatively long and slender fibres for a hardwood. The thin walls cause the fibre to collapse upon drying, giving a paper with low bulk and low opacity. The birch fibres are, however, easily fibrillated and give about 75% of the tensile strength of softwood. The low opacity makes it suitable for making glassine. In India, the birch (Sanskrit: भुर्ज, bhurja) holds great historical significance in the culture of North India, where the thin bark coming off in winter was extensively used as writing paper. Birch paper (Sanskrit: भुर्ज पत्र, bhurja patra) is exceptionally durable and was the material used for many ancient Indian texts. The Roman period Vindolanda tablets also use birch as a material on which to write and birch bark was used widely in ancient Russia as notepaper (beresta) and for decorative purposes and even making footwear (lapti) and baskets.
== Clinical significance == Recessive mutations in NADK2 cause NADK2 deficiency, an inherited metabolic disorder characterized by neurological symptoms including hypotonia, developmental delay, ataxia, and encephalopathy. Affected individuals also show metabolic abnormalities, including hyperlysinemia and impaired fat oxidation with elevated C10:2-carnitine levels, consistent with secondary 2,4-dienoyl-CoA reductase deficiency. Cancer cells are exposed to elevated oxidative stress and are consequently highly dependent on mitochondrial NADPH to maintain redox homeostasis. NADK2 is essential for mitochondrial NADPH production and has therefore been proposed as a potential target to increase oxidative stress and sensitize cancer cells to apoptosis. A lack of NADK2 additionally impairs proline biosynthesis, rendering cancer cells dependent on exogenous proline for proliferation. NADK2 has been linked to Alzheimer's disease. Tau oligomers upregulate NADK2 in human neurons, leading to increased mitochondrial NADPH production, which in turn increases LRP1 expression and promotes tau uptake, creating a self-reinforcing cycle.
A chaotropic agent is a molecule in water solution that can disrupt the hydrogen bonding network between water molecules (i.e. exerts chaotropic activity). This has an effect on the stability of the native state of other molecules in the solution, mainly macromolecules (proteins, nucleic acids) by weakening the hydrophobic effect. For example, a chaotropic agent reduces the amount of order in the structure of a protein formed by water molecules, both in the bulk and the hydration shells around hydrophobic amino acids, and may cause its denaturation. Conversely, an antichaotropic agent (kosmotropic) is a molecule in an aqueous solution that will increase the hydrophobic effects within the solution. Antichaotropic salts such as ammonium sulphate can be used to precipitate substances from the impure mixture. This is used in protein purification processes, to remove undesired proteins from solution.
Sources: en.wikipedia.org
It is a glucagon-like peptide-1 receptor agonist, often grouped with the incretin mimetics. Its backbone is modified from the human hormone to resist enzymatic degradation and to bind albumin. These two features distinguish it from the native peptide.
No. It shares high sequence identity but carries non-natural modifications that alter its stability and clearance. The naturally occurring hormone is broken down within minutes, while the synthetic analogue circulates far longer.
Attachment to serum albumin reduces renal filtration of the peptide and shields it from enzymatic breakdown. The consequence is a much longer interval between administrations than unmodified peptides allow. The precise contribution of binding affinity to overall duration is still being quantified.
It is given either as a once-weekly subcutaneous injection or as an oral tablet taken once daily. The two forms use different absorption strategies, so they are not interchangeable on a milligram-for-milligram basis.